Table 4.
Annual results of universal and targeted RV vaccination compared to no vaccination under base-case assumptions
| RV disease burden (95% CI)a | RV disease costsa (€ million) | Vaccination costs (€ million) | |||||
|---|---|---|---|---|---|---|---|
| |
Disease episodes (x1000) |
Hospitalizationsb |
Fatal cases |
QALY’s lost (undiscounted) |
Direct healthcare costs (undiscounted) |
Societal costs (undiscounted) |
(undiscounted) |
|
No vaccination |
74.1(57.8; 90.0) |
4,870 (4,310; 5,430) |
6.5 (3.2; 11.0) |
257 (136; 422) |
11.9 (10.5; 13.3) |
18.2 (16.2; 20.3) |
- |
|
Targeted RV vaccination |
|
|
|
|
|
|
|
| RV1 |
67.3 (51.3; 82.4) |
4,370 (3,890; 4,870) |
0.7(0.2; 1.6) |
119 (79; 177) |
10.5 (9.3; 11.8) |
16.4 (14.6; 18.2) |
1.5 |
| Percent reduction |
8% |
10% |
89% |
54% |
12% |
10% |
|
| RV5 |
67.4 (51.5; 82.7) |
4,384 (3,892; 4,870) |
0.8 (0.3; 1.7) |
121 (80; 184) |
10.6 (9.4; 11.8) |
16.4 (14.6; 18.2) |
1.6 |
| Percent reduction |
8% |
10% |
88% |
53% |
11% |
10% |
|
|
Universal RV vaccination |
|
|
|
|
|
|
|
| RV1 |
40.6 (30.1; 51.2) |
1,370 (1,150; 1,650) |
0.4 (0.2; 0.8) |
60 (42; 81) |
3.4 (2 8; 4 1) |
5.9 (5.0; 6.9) |
15.2 |
| Percent reduction |
45% |
72% |
94% |
77% |
71% |
67% |
|
| RV5 |
42.6 (31.7; 53.6) |
1,440 (1,210; 1,710) |
0.5(0.2; 0.9) |
66 (45; 91) |
3.6 (3.1; 4.3) |
6.3 (5.3; 7.3) |
16.7 |
| Percent reduction | 43% | 70% | 92% | 75% | 70% | 65% | |
aResults reflect those five years and more after initial implementation of a vaccination strategy when steady state is reached; bincluding nosocomial infections. CI:confidence interval; QALY:quality-adjusted life year; RV: rotavirus.